Drug Trial Radar · NCT04075266
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
23
Actual
Start
Jan 9, 2020
Primary completion
Oct 5, 2023
Study completion Apr 26, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
Conditions
- Multiple Sclerosis
Interventions
OcrelizumabDrug
Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks. Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Exploration Period: Area Under the Concentration Versus Time Curve of OcrelizumabTime frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
- Dose Exploration Period: Maximum Concentration (Cmax) of OcrelizumabTime frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
- Dose Exploration Period: Levels of CD 19+ B-cell Count in BloodTime frame: At Week 24
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
University of Colorado Denver Childrens Hospital Rocky Mountain MS Center
Aurora, Colorado
Childrens National Health Center
Washington D.C., District of Columbia
Boston Childrens Hospital
Boston, Massachusetts
Washington Universtiy school of Medicine
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Ospedale Pediatrico Bambino Gesù
Rome, Lazio, Italy
Azienda Ospedaliera Sant'Andrea
Rome, Lazio, Italy
AOU Policlinico V. Emanuele - P.O G. Rodolico
Catania, Sicily, Italy
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, Poland
Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego
Warsaw, Poland
Instytut Pomnik Centrum Zdrowia Dziecka
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.